KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non-Current Deffered Revenue: 2020-2024

Historic Non-Current Deffered Revenue for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to $118.8 million.

  • Recursion Pharmaceuticals' Non-Current Deffered Revenue rose 607.76% to $111.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.2 million, marking a year-over-year increase of 607.76%. This contributed to the annual value of $118.8 million for FY2024, which is 131.79% up from last year.
  • As of FY2024, Recursion Pharmaceuticals' Non-Current Deffered Revenue stood at $118.8 million, which was up 131.79% from $51.2 million recorded in FY2023.
  • Recursion Pharmaceuticals' Non-Current Deffered Revenue's 5-year high stood at $118.8 million during FY2024, with a 5-year trough of $6.7 million in FY2021.
  • In the last 3 years, Recursion Pharmaceuticals' Non-Current Deffered Revenue had a median value of $70.3 million in 2022 and averaged $80.1 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first crashed by 60.00% in 2021, then spiked by 953.86% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Non-Current Deffered Revenue (Yearly) stood at $16.7 million in 2020, then plummeted by 60.00% to $6.7 million in 2021, then skyrocketed by 953.86% to $70.3 million in 2022, then declined by 27.07% to $51.2 million in 2023, then spiked by 131.79% to $118.8 million in 2024.